Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Compass Therapeutics Inc. (CMPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: CMPX (4-star) is a STRONG-BUY. BUY since 24 days. Profits (32.38%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.22
1 Year Target Price $13.22
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 179.71% | Avg. Invested days 32 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 384.42M USD | Price to earnings Ratio - | 1Y Target Price 13.22 |
Price to earnings Ratio - | 1Y Target Price 13.22 | ||
Volume (30-day avg) 9 | Beta 1.22 | 52 Weeks Range 0.82 - 4.08 | Updated Date 07/4/2025 |
52 Weeks Range 0.82 - 4.08 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7273.06% |
Management Effectiveness
Return on Assets (TTM) -26.41% | Return on Equity (TTM) -41.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 278171344 | Price to Sales(TTM) 452.26 |
Enterprise Value 278171344 | Price to Sales(TTM) 452.26 | ||
Enterprise Value to Revenue 327.26 | Enterprise Value to EBITDA -8.92 | Shares Outstanding 138282000 | Shares Floating 88910115 |
Shares Outstanding 138282000 | Shares Floating 88910115 | ||
Percent Insiders 14.16 | Percent Institutions 70.02 |
Upturn AI SWOT
Compass Therapeutics Inc.
Company Overview
History and Background
Compass Therapeutics Inc. is a clinical-stage biotechnology company focused on developing proprietary antibody therapeutics to treat cancer. It was founded in 2014. The company aims to develop novel treatments to improve patient outcomes. Compass went public via reverse merger in 2019. Prior to that, it was funded by venture firms.
Core Business Areas
- Antibody Therapeutics Development: Compass Therapeutics focuses on developing antibody-based therapies for cancer. They utilize their proprietary StitchMabs and common light chain (CLC) platforms to discover and develop multispecific antibodies.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates. These trials involve testing the drugs on human subjects.
- Partnerships and Licensing: Compass seeks partnerships and licensing agreements with other pharmaceutical companies to expand the development and commercialization of its products.
Leadership and Structure
The leadership team includes key executives responsible for research, development, finance, and operations. The organizational structure is typical for a biotech company, with departments focused on drug discovery, clinical development, and corporate functions. CEO is Vered Nayshtut, PhD
Top Products and Market Share
Key Offerings
- CTX-471 (anti-CD137 antibody): CTX-471 is a fully human agonistic antibody targeting CD137 (4-1BB), a key co-stimulatory receptor on T cells and NK cells. It's being developed for solid tumors. The company released positive clinical trial data in combination with pembrolizumab. Competitors include other CD137 agonists in development by larger pharma companies.
- CTX-857 (anti-PD1 antibody): CTX-857 is a PD-1 blocking antibody designed to offer improved efficacy and tolerability compared to existing anti-PD-1 therapies. It is in pre-clinical stage. Competitors include pembrolizumab (Keytruda), nivolumab (Opdivo), and other PD-1/PD-L1 inhibitors.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the immuno-oncology segment, is highly competitive and rapidly evolving. There is significant investment and innovation in antibody-based therapies.
Positioning
Compass Therapeutics is positioned as a clinical-stage company with a focus on innovative antibody therapies. Its proprietary technology platforms provide a competitive advantage in developing novel multispecific antibodies.
Total Addressable Market (TAM)
The TAM for immuno-oncology therapies is estimated to be in the tens of billions of dollars annually and is expected to grow. Compass is targeting specific niches within this market with its differentiated antibody technologies. The PD-1 TAM is estimated around $40B.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (StitchMabs, CLC)
- Focus on novel antibody therapeutics
- Experienced management team
- Positive early clinical data for CTX-471
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial success
- Limited number of products in late-stage development
- High risk of failure inherent in drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new therapeutic candidates
- Positive clinical trial results leading to regulatory approval
- Growing market for immuno-oncology therapies
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
Competitive Landscape
Compass Therapeutics is a smaller player in the immuno-oncology market competing with larger pharmaceutical companies. Its competitive advantage lies in its proprietary technology platforms and novel antibody candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on the specific period examined, as it is still a relatively young and developing company.
Future Projections: Future projections depend on analyst estimates, clinical trial outcomes, and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing CTX-471 in clinical trials, developing new antibody candidates, and seeking partnerships.
Summary
Compass Therapeutics is a clinical-stage biotech company focused on novel antibody therapeutics, particularly in immuno-oncology. The company's strength lies in its proprietary technology and early clinical data. However, it faces challenges due to its limited resources and dependence on clinical trial success, while it needs to look out for larger competitors. Its prospects depend on securing partnerships and favorable clinical trial outcomes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-05 | CEO & Vice Chairman Dr. Thomas J. Schuetz M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | |
Full time employees 35 | |||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.